Company intelligence / Profile preview

Nuwellis

Minneapolis, Minnesota, United States

Ownership: Public · NUWE
Development stage: Commercial

Overview

Nuwellis is a commercial-stage medical device company focused on transforming care for patients suffering from fluid overload. Its main product, the Aquadex SmartFlow System, is FDA-cleared and used clinically in both adult and pediatric populations who do not respond to standard medical management such as diuretics. The system provides ultrafiltration therapy that gently removes excess isotonic fluid (water and sodium), restoring balance with predictable outcomes. The company has demonstrated clinical utility in real-world settings but faces financial challenges as of mid 2025.

Therapeutic areas: CardiovascularNephrology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Aquadex SmartFlow

Commercial

Indications: Fluid Overload, Chronic Heart Failure

Financials

Market cap: $72.6K
Total revenue: $2M
Enterprise value: $-3.6M

Beyond the preview

Go deeper on Nuwellis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuwellis.

Explore the full profile